EXHIBIT 99.2

                                  PRESS RELEASE





                  ENDOVASC ANNOUNCES NEW TRADING SYMBOL - EVSC

            FORWARD 6-FOR-5 STOCK SPLIT AND REINCORPORATION IN NEVADA

MONTGOMERY,  TX  -  MARCH 31, 2003 - ENDOVASC LTD. INC. (OTCBB:ENVC - NEWS) - an
                                                               ----   ----
early-stage  drug  development  company  that  pioneers  new  cardiovascular and
metabolic  drug  therapies, announced today that effective April 1, 2003 it will
begin  trading on the over-the-counter bulletin board market under the new stock
ticker  "EVSC" and CUSIP Number 29267B102.  The old shares of ENVC will cease to
trade  effective  March  31,  2003.  The  new  stock  will  begin  trading  on a
post-split  6-for-5  basis  on  April  1,  2003.

On  February  24,  2003,  Endovasc Ltd., Inc., a Delaware corporation ("Endovasc
Delaware")  and  Endovasc, Inc. a Nevada corporation ("Endovasc Nevada") entered
into an Agreement and Plan of Merger ("Merger Agreement"). The merger, which has
been  approved  by  the  Board  of  Directors of each company, was approved by a
majority  of the holders of the issued and outstanding capital stock of Endovasc
Delaware  on  March  11,  2003,  and  became  effective  on  March  31,  2003.

Upon  the  terms and subject to the conditions set forth in the Merger Agreement
and  in  accordance  with Nevada law, Endovasc Delaware shall be merged with and
into  Endovasc  Nevada.  As  a  result  of the merger, the outstanding shares of
capital  stock of Endovasc Delaware shall be converted or canceled in the manner
provided  in  Section 2.01 of the Agreement, the separate corporate existence of
Endovasc  Delaware  shall  cease,  and  Endovasc  Nevada  will  be the surviving
corporation  in  the  Merger.

ABOUT  ENDOVASC

Endovasc  Ltd.  Inc.,  established  in  1996, is an early-stage drug development
company  that  pioneers new cardiovascular and metabolic drug therapies that are
designed  to deliver and release drugs to their intended targets in an efficient
and  controlled manner.  Endovasc's lead drug candidates include Angiogenix(TM),
Liprostin(TM),  PROStent(TM)  stent-coating technology, biodegradable stents and
other  drug-delivery  stents.

CONTACT:
FOCUS Partners LLC
David Zazoff, 212/752-9445
envc@focuspartners.com